Cancer treatments have advanced significantly, offering options that were unimaginable for some patients two decades ago. One recent example is a randomised controlled trial involving 1,137 people with high-risk melanoma that had been surgically removed but remained likely to return.
Participants received either pembrolizumab, an established immunotherapy, or pembrolizumab combined with an experimental mRNA vaccine tailored to help the immune system recognise targets specific to each patient’s tumour. After two years, 82.2% of those receiving the combination were alive without a recurrence, compared with 70% of those given pembrolizumab alone. The combination also reduced the relative risk of distant metastasis or death by 38%.
The results suggest that personalised vaccines could become an important addition to cancer treatment, although it remains unclear whether similar benefits will appear in other cancers. Overall survival data are not yet mature, and quality-of-life information from the trial is not yet available. Fever, pain at the injection site and fatigue were common, while severe treatment-related adverse events occurred at similar rates in both groups.
The progress raises a broader question: what is life like for the people receiving increasingly effective treatments? Delaying a cancer’s return can come with side-effects, fatigue, impaired mobility, psychological trauma, financial pressure and disruption to family and working life.
A scan showing no evidence of cancer does not necessarily mean that a patient can sleep, work or enjoy daily activities normally. A retired academic approaching 90, for example, regarded getting home safely as more important than pursuing an intervention that could seriously reduce their quality of life. Other patients may prioritise earning an income, caring for children or remaining independent.
These priorities are not competing definitions of success. A treatment offering a cure or additional months of life may be worthwhile despite considerable toxicity for one person, while another may judge its effects on work, family or independence differently. Oncologists therefore need to understand what each patient hopes treatment will achieve and explain what they may have to endure to reach that goal.
Quality of life is often reported less rigorously than tumour response, recurrence and survival. Fewer than a third of trials report quality-of-life measures in their primary publication, and only about half publish them at all. A recent paper in The Lancet Oncology has called for improved reporting in trials of adjuvant treatments, including information on how many patients experience a clinically meaningful deterioration, how long it lasts and whether they recover.
Collecting these data can be difficult. Questionnaires may burden sick patients, and doctors may assess quality of life differently from their patients. But missing information should prompt better methods rather than less attention. Patients need to know not only how likely a treatment is to work, but also how it could affect their daily lives.
Modern therapies have extended many lives, and personalised medicine may bring further gains. However, progress should be measured by more than scans or survival curves. Quality-of-life outcomes need to be collected carefully, discussed openly and treated as a central part of cancer care. The goal should be not only to keep people alive, but also to protect the lives they want to live.
Sources: The Guardian Science.